5^th Global Pharmacists Annual Meeting July 14-15, 2016 Brisbane, Australia

Ping Zhou has completed her BS degree study from Fudan University, China, and PhD degree and Post-doctoral studies from The Chinese University of HongrnKong. She was appointed as a staff member at Fudan University and promoted to full Professor in 2005. She has focused on the research of biomedicine materialsrnand developed new drugs from natural herbs for diabetes treatment. She has published more than 100 scientifi c papers and got First Prize of Science andrnTechnology Award (Natural Science), Ministry of Education of China (2004), Wang Tianjuan Award for Magnetic Resonance Spectroscopy in China (2006), andrnFirst Prize of Shanghai Natural Science Award (2011).

Inhibition of protein tyrosine phosphatase 1B (PTP1B) activity has been considered as a promising therapy approach to treat typern2 diabetes. In this work, a novel PTP1B activity inhibitor, named FYGL (Fudan-Yueyang-G. lucidum), was screened from thernfruiting bodies of Ganoderma lucidum, and showed an effi cient PTP1B inhibitory potency with IC50=5.12±0.05μg/mL. Th e type 2rndiabetic animals treated orally by FYGL showed an obvious decrease in the plasma glucose level, and comparable with those treatedrnby metformin, a clinic drug. Th e toxicity of FYGL is very low. FYGL is a water soluble hyperbranched proteoglycan with molecularrnweight (Mη) of 105. In addition, it was also found that FYGL could protect against the renal functional and morphologic injuries byrnincreasing the activities of antioxidants and inhibiting the accumulation of oxidation. Th e results indicate that FYGL may serve as arndrug candidate or a health-care food for the diabetic therapy and renal functional protection.